Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 4/20 | 0.50 |
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | CA7 | P43166 | 4/20 | 0.50 |
| ▸ | CA9 | Q16790 | 4/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9407152 | 0.86 | HSP90AB1 (0.58) | HSP90AB1HTTCA12CA1CA2 | |
| SCHEMBL9407157 | 0.86 | HSP90AB1 (0.58) | HSP90AB1HTTCA12CA1CA2 | |
| SCHEMBL3559437 | 0.81 | CA12 (0.51) | HSP90AB1HTTCA12CA1CA2 | |
| SCHEMBL22955842 | 0.79 | LMNA (0.46) | HTTCA12CA1CA2CA7 | |
| SCHEMBL29378476 | 0.78 | CA12 (0.59) | HSP90AB1HTTCA12CA1CA2 | |
| SCHEMBL1830213 | 0.78 | CA12 (0.59) | HSP90AB1HTTCA12CA1CA2 | |
| SCHEMBL20026813 | 0.78 | TERT (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9405634 | 0.77 | HTT (0.46) | HTTKDM4EALDH1A1LMNAHPGD | |
| SCHEMBL9405633 | 0.77 | HTT (0.46) | HTTKDM4EALDH1A1LMNAHPGD | |
| SCHEMBL2989013 | 0.77 | CA12 (0.58) | HSP90AB1HTTCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318217-B2 | Compositions comprising an anti-inflammatory blend | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20110081431-A1 | COMPOSITIONS COMPRISING AN NFkB-INHIBITOR AND A NON-RETINOID COLLAGEN PROMOTER | KENVUE BRANDS LLC | 2011-04-07 | — | — | US | disclosed |
| US-20110081433-A1 | COMPOSITIONS COMPRISING AN ANTI-INFLAMMATORY BLEND | JOHNSON & JOHNSON CONSUMER INC. | 2011-04-07 | — | — | US | disclosed |
| US-20110081430-A1 | COMPOSITIONS COMPRISING AN NFkB-INHIBITOR AND A TROPOELASTIN PROMOTER | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110081431-A1 | COMPOSITIONS COMPRISING AN NFkB-INHIBITOR AND A NON-RETINOID COLLAGEN PROMOTER | NFKBIA, NFRKB, NFKB1 | HSP90AB1 536/4885HTT 3686/4885CA12 2948/4885 |
| US-20110081430-A1 | COMPOSITIONS COMPRISING AN NFkB-INHIBITOR AND A TROPOELASTIN PROMOTER | NFKBIA, NFKB1, NFKB2 | HSP90AB1 217/4885HTT 620/4885CA12 4182/4885 |
| US-20110081433-A1 | COMPOSITIONS COMPRISING AN ANTI-INFLAMMATORY BLEND | NFKBIA, NFKB2, NFKB1 | HSP90AB1 629/4885HTT 1636/4885CA12 4775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.